• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

(CAS: 1427043-06-8)

Suppliers of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Company Name Email Tel Country
Shanghai Haoyuan Chemexpress Co., Ltd. [email protected] +86 (21) 5187-0955 / +86 (21) 5895-5995 China

Fax: +86 (21) 5895-5996Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Solubility of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Solubility Sources

Storage Condition of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways
Target
Research Area
Indications

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- - No Development Reported

Chemical Information

M.Wt Formula CAS No. Synonyms
646.66 C38H55BN2O6 1427043-06-8 (3R,5R,6S)-tert-butyl 2-oxo-5,6-diphenyl-3-(2-(piperidin-1-yl)ethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl)morpholine-4-carboxylate

Structure Information of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Smiles O=C(N1[[email protected]](CCCCB2OC(C)(C)C(C)(C)O2)(CCN3CCCCC3)C(O[[email protected]@H](C4=CC=CC=C4)[[email protected]]1C5=CC=CC=C5)=O)OC(C)(C)C
InChI InChI=1S/C38H55BN2O6/c1-35(2,3)45-34(43)41-31(29-19-11-8-12-20-29)32(30-21-13-9-14-22-30)44-33(42)38(41,24-28-40-26-17-10-18-27-40)23-15-16-25-39-46-36(4,5)37(6,7)47-39/h8-9,11-14,19-22,31-32H,10,15-18,23-28H2,1-7H3/t31-,32+,38-/m1/s1

Related Products

Other Form Products of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Safety Data of 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)-

Hazard Symbols: Risk Statements: Safety Statements:
Transport Information: HS Code: RTECS:
WGK Germany:

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Reference

Tags: buy 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- IC50 | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- price | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- cost | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- solubility | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- purchase | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- manufacturer | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- research buy | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- order | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- MSDS | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- chemical structure | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Storage condition | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- molecular weight | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- mw | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- datasheet | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- supplier | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- cell line | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- NMR | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- MS | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- IR | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- solubility | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Safe information | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Qc and Spectral Information | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Clinical Information | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Clinical Trial | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- Route of Synthesis | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- storage condition | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- diseases and conditions | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- flash point | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- boiling point | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- melting point | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- storage condition | 4-Morpholinecarboxylic acid, 2-oxo-5,6-diphenyl-3-[2-(1-piperidinyl)ethyl]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-, 1,1-dimethylethyl ester, (3R,5R,6S)- brand